Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study - 29/01/13
, William E Brady, PhD b, Vinod Vathipadiekal, PhD c, Heather A Lankes, PhD b, Robert Coleman, ProfMD d, Mark A Morgan, ProfMD e, Robert Mannel, ProfMD f, S Diane Yamada, ProfMD g, David Mutch, ProfMD h, William H Rodgers, ProfMD i, Michael Birrer, MD c, David M Gershenson, MD dSummary |
Background |
Low-grade serous carcinoma of the ovary is chemoresistant but mutations in the MAPK pathway could be targeted to control tumour growth. We therefore assessed the safety and activity of selumetinib, an inhibitor of MEK1/2, for patients with this cancer.
Methods |
In this open-label, single-arm phase 2 study, women (aged ≥18 years) with recurrent low-grade serous ovarian or peritoneal carcinoma were given selumetinib (50 mg twice daily, orally) until progression. The primary endpoint was the proportion of patients who had an objective tumour response according to RECIST version 1.1, assessed for all the treated patients. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00551070.
Findings |
52 patients were enrolled between Dec 17, 2007, and Nov 23, 2009. All were eligible for analyses. Eight (15%) patients had an objective response to treatment—one patient had a complete response and seven had partial responses. 34 (65%) patients had stable disease. There were no treatment-related deaths. Grade 4 toxicities were cardiac (one), pain (one), and pulmonary events (one). Grade 3 toxicities that occurred in more than one patient were gastrointestinal (13), dermatological (nine), metabolic (seven), fatigue (six), anaemia (four), pain (four), constitutional (three), and cardiac events (two).
Interpretation |
Selumetinib is well tolerated, and is active in the treatment of recurrent low-grade serous carcinoma of the ovary or peritoneum. The findings suggest that inhibitors of the MAPK pathway warrant further investigation in these patients.
Funding |
National Cancer Institute.
Le texte complet de cet article est disponible en PDF.Plan
Vol 14 - N° 2
P. 134-140 - février 2013 Retour au numéro
Article précédent
- Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
- Istvan Lang, Thomas Brodowicz, Larisa Ryvo, Zsuzsanna Kahan, Richard Greil, Semir Beslija, Salomon M Stemmer, Bella Kaufman, Zanete Zvirbule, Günther G Steger, Bohuslav Melichar, Tadeusz Pienkowski, Daniela Sirbu, Diethelm Messinger, Christoph Zielinski, on behalf of the Central European Cooperative Oncology Group †
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- Daniel YC Heng, Wanling Xie, Meredith M Regan, Lauren C Harshman, Georg A Bjarnason, Ulka N Vaishampayan, Mary Mackenzie, Lori Wood, Frede Donskov, Min-Han Tan, Sun-Young Rha, Neeraj Agarwal, Christian Kollmannsberger, Brian I Rini, Toni K Choueiri
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?